RAC

0.60%

$1.69 race oncology ltd

Ann: Race Oncology 2023 Chair's Address & AGM Presentation, page-71

First 71 Last

Share
Profile

Follow
Wapps01

28 Posts.

29/11/23

14:51

Post #: 71171524
Share
Originally posted by RitzyBusiness: ↑

I just found out about Charlie Mungers passing from another HC RAC post. He was one of the most rationale investors.

Here is my favorite quote from Munger, that definitely applies to RAC with Dr T’s CEO options with exercise price of $4.25 above ATH. I have never experienced executive options priced at almost 5x current sp!!!!! Usually only 1.5x or 2x.

I was also in attendance at the AGM in Sydney. My feedback …

Dr T is more bullish than ever on prospects. Triangle report and targets are too conservative.
PS is an excellent addition as ED. He is eager to start business development and marketing to institutions. Road show to come. This is his love and passion and he has over 10 years experience as sell side equity analyst from UBS and HSBC. He knows how to sell a good equity story. I just wished PS can be 100% dedicated on RAC. IMO, His past experience as equity analyst and biotech exec, beats pharma drug sales experience.
Key management personnel all on board with strategy and Dr T’s leadship and vision.

My view:

I wouldnt be surprised if insiders (directors and management) start to accumulate at these levels. This is the sense I got from talking one on one with a number of RAC team members.
My reflection on why Dr T, was not also made MD when the last 3 CEOs were also MD … a director needs to disclose trades within 5 business days (no matter how small the trade), whilst non-director (who is a significant (>5%) holder) only need to disclose trades after 1% movement in holdings, for RAC that is accumulation or reductions of holdings of over 1.63m shares. Could Dr T still want to accumulate and only want to disclose after accumulating another 1.63m? He will not be reducing IMO! This is just my speculation after the AGM, I didn’t discuss this with Dr T.
The RAC incentives (bonus options and CEO package) are set with shareholders in mind …. Hence I am confident of a positive outcome for all of us holders.
Time for me to look forward and stop looking in read view mirror. We all have the same choice … buy, hold or sell at this time. We can’t redo or undo the past.
I was buying during the AGM and after.

Expand

I was also excited by His past experience as equity analyst and biotech exec and as you say beats pharma drug sales experience.
RAC Price at posting: 88.5¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

AZY

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

MLS

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

MKG

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

ENV

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

ASN

Utah authorities sign off on Anson's lithium extraction plans at Green River

VUL

Vulcan appoints investment bank and M&A veteran to board

MM8

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

NAM

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

There are more pages in this discussion • 5 more messages in this thread...

First 71 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.69		Change 0.010(0.60%)		Mkt cap ! $287.1M

Open	High	Low	Value	Volume
$1.69	$1.70	$1.65	$89.01K	53.2K

Buyers (Bids)

No.	Vol.	Price($)
1	2342	$1.69

Sellers (Offers)

Price($)	Vol.	No.
$1.70	5	1

View Market Depth

No.	Vol.	Price($)
1	2342	1.685
1	3664	1.680
1	5077	1.660
1	1265	1.650
1	612	1.635

Price($)	Vol.	No.
1.695	5	1
1.700	11000	1
1.730	2399	1
1.750	952	2
1.775	1328	1

Last trade - 16.10pm 13/09/2024 (20 minute delay)

RAC (ASX) Chart

Ann: Race Oncology 2023 Chair's Address & AGM Presentation, page-71

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Utah authorities sign off on Anson's lithium extraction plans at Green River

Vulcan appoints investment bank and M&A veteran to board

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Race Oncology 2023 Chair's Address & AGM Presentation, page-71

Top Stories

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Utah authorities sign off on Anson's lithium extraction plans at Green River

Vulcan appoints investment bank and M&A veteran to board

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News